Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jul 14, 2025; 31(26): 109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285
Figure 3
Figure 3 Dynamic changes in lipid profiles between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B. A-E: The two groups exhibited comparable virological performance regarding cholesterol (A), low-density lipoprotein (B), high-density lipoprotein (C), triglycerides (D) and the triglycerides/high-density lipoprotein ratio (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; CHOL: Cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; TG: Triglycerides; TC: Total cholesterol.